DOCSLIB.ORG

Biochemical Characterization of Glutamate Decarboxylase from Brucella Microti and Escherichia Coli

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biochemical Characterization of Glutamate Decarboxylase from Brucella Microti and Escherichia Coli DOTTORATO DI RICERCA IN BIOCHIMICA CICLO XXVI (A.A. 2010-2013) Biochemical characterization of glutamate decarboxylase from Brucella microti and Escherichia coli Asp86* Asp86* Phe463 Lys276 His275 Lys276 His275 His465 Acetate Lys464 Ala245 Ala245 Thr466 Asp243 Gln163 Asp243 Gln163 Docente guida Coordinatore Prof. Roberto Contestabile Prof. Francesco Malatesta Tutor Prof.ssa Daniela De Biase Dottoranda Gaia Grassini Dicembre 2013 DOTTORATO DI RICERCA IN BIOCHIMICA CICLO XXVI (A.A. 2010-2013) Biochemical characterization of glutamate decarboxylase from Brucella microti and Escherichia coli Dottoranda Gaia Grassini Docente guida Coordinatore Prof. Roberto Contestabile Prof. Francesco Malatesta Tutor Prof.ssa Daniela De Biase Dicembre 2013 INDEX 1 Introduction ................................................................................................. 1 1.1 Glutamate decarboxylase-dependent acid resistance in orally- acquired bacteria ............................................................................................ 2 1.1.1 Acid resistance in orally-acquired bacteria ............................................. 2 1.1.2 The GDAR system: function and regulation ........................................... 6 1.1.3 The GDAR system: structural components ........................................... 11 1.1.3.1 GadC .................................................................................................. 12 1.1.3.2 GadB .................................................................................................. 14 1.2 Glutamate decarboxylase ...................................................................... 18 1.2.1 Glutamate decarboxylases ..................................................................... 18 1.2.2 Biochemical insights into Escherichia coli GadB ................................ 21 1.2.3 Bacterial Gads ....................................................................................... 26 1.2.4 Eukaryotic Gads .................................................................................... 30 1.3 Biotechnological aspects ........................................................................ 37 1.3.1 GABA production by GDAR system in health and disease ................. 37 1.3.2 The application of glutamate decarboxylase in the manufacturing of biobased industrial chemicals ........................................................................ 38 1.4 Aims ......................................................................................................... 42 2 Materials and Methods ............................................................................. 44 2.1 Growth media, bacterial strains and plasmids .................................... 45 2.2 N-terminal sequence determination of BmGadB ................................ 51 2.3 Recombinant DNA techniques .............................................................. 52 2.3.1 Purification of plasmid DNA, digestion with restriction enzymes and electrophoresis ............................................................................................... 52 2.3.2 Competent cells: preparation and transformation ................................. 53 2.3.3 PCR ....................................................................................................... 54 2.4 Cloning of BmGadB ............................................................................... 55 2.4.1 Preparative PCR .................................................................................... 55 2.4.2 Cloning with Strataclone PCR Cloning Kit .......................................... 56 2.4.3 Cloning into pET3a ............................................................................... 57 2.5 Expression and purification of EcGadB and BmGadB ...................... 59 2.5.1 Growth and induction of the bacterial culture ...................................... 60 2.5.2 Bacterial lysis, precipitation of nucleic acids and ammonium sulphate fractionation ................................................................................................... 61 2.5.3 DEAE-Sepharose chromatography ....................................................... 61 2.5.4 Determination of Gad and cofactor concentration ................................ 63 2.5.5 ApoGadB production ............................................................................ 64 2.6 Analytical techniques ............................................................................. 64 2.6.1 Gad test (Rice test) ................................................................................ 64 2.6.2 GABA assay .......................................................................................... 65 2.6.3 Gad activity assay ................................................................................. 66 2.6.4 Isotope effect ......................................................................................... 67 2.6.5 Protein assays ........................................................................................ 68 2.6.6 SDS-PAGE electrophoresis and immunoblot analysis ......................... 69 2.6.7 Gel filtration chromatography ............................................................... 70 2.6.8 Spectroscopic analysis........................................................................... 71 2.6.8.1 Steady-state spectroscopy .................................................................. 71 2.6.8.2 Fluorescence ....................................................................................... 72 2.6.9 Cell fractionation ................................................................................... 74 2.7 Crystallization and structural analysis of the apo form of EcGadB . 75 2.7.1 Protein crystallization ........................................................................... 75 2.7.2 X-ray Diffraction Experiment ............................................................... 77 2.8 Data Analysis .......................................................................................... 79 3 Results and Discussion .............................................................................. 80 3.1 PART I: Biochemical and spectroscopic properties of recombinant glutamate decarboxylase from Brucella microti ....................................... 81 3.1.1 Effect of the heterologous expression of B. microti gadBC in an E. coli acid-sensitive mutant strain ............................................................................ 83 3.1.2 Expression and purification of recombinant BmGadB ......................... 88 3.1.3 pH-dependent absorbance and activity changes ................................... 93 3.1.4 Fluorescence properties ......................................................................... 98 3.1.5 pH-dependent cellular partition .......................................................... 101 3.1.6 Discussion ........................................................................................... 103 3.2 PART II: The Asp86-His465 mutant of Escherichia coli glutamate decarboxylase exhibits improved GABA synthesis at alkaline pH ........ 106 3.2.1 Preliminary data: purification and spectroscopic properties of GadB- D86NH465A ................................................................................................ 108 3.2.2 Catalytic Properties ............................................................................. 111 3.2.2.1 Effect of pH on specific activity ...................................................... 111 3.2.2.2 Kinetic constants and solvent isotopic effect ................................... 114 3.2.3 Structural analysis ............................................................................... 116 3.2.4 Discussion ........................................................................................... 117 3.3 PART III: Preliminary structural analysis of Escherichia coli glutamate decarboxylase apo form ........................................................... 122 3.3.1 Gel filtration chromatography ............................................................. 123 3.3.2 Crystallization and structural analysis................................................. 126 3.3.3 Discussion ........................................................................................... 127 3.4 Conclusions and perspectives .............................................................. 129 4 References ................................................................................................ 131 5 Publications .............................................................................................. 150 Abbreviations used GIT gastrointestinal tract SCFAs short chain fatty acids AR acid resistance PLP pyridoxal 5’-phosphate GDAR glutamate-dependent AR ADAR arginine-dependent AR Gad glutamate decarboxylase GABA γ-aminobutyrate AFI acid fitness island PMP pyridoxamine 5'-phosphate LAB Lactic Acid Bacteria CaM calmodulin CaMBD Ca2+/calmodulin Binding Domain AID autoinhibitory domains ORF open reading frame DTT dithiothreitol SDS sodium dodecyl sulphate SDS-PAGE SDS-polyacrylamide gel electrophoresis DEAE diethylethanolamine HEPPS 3-[4-(2-Hydroxyethyl)-1-piperazinyl]propanesulfonic acid BmGadB Brucella microti GadB EcGadB Escherichia coli GadB DDC L-DOPA decarboxylase Introduction 1 1.1 Glutamate decarboxylase-dependent acid resistance in orally-acquired bacteria 1.1.1 Acid resistance in orally-acquired bacteria Acid stress is one of the most hostile conditions for the bacterial cell. Generally,
Load more

Recommended publications
  • The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’S Disease
    life Review The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease Gianfranco Natale 1,2,* , Larisa Ryskalin 1 , Gabriele Morucci 1 , Gloria Lazzeri 1, Alessandro Frati 3,4 and Francesco Fornai 1,4 1 Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy; [email protected] (L.R.); [email protected] (G.M.); [email protected] (G.L.); [email protected] (F.F.) 2 Museum of Human Anatomy “Filippo Civinini”, University of Pisa, 56126 Pisa, Italy 3 Neurosurgery Division, Human Neurosciences Department, Sapienza University of Rome, 00135 Rome, Italy; [email protected] 4 Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Neuromed, 86077 Pozzilli, Italy * Correspondence: [email protected] Abstract: The gastrointestinal (GI) tract is provided with a peculiar nervous network, known as the enteric nervous system (ENS), which is dedicated to the fine control of digestive functions. This forms a complex network, which includes several types of neurons, as well as glial cells. Despite extensive studies, a comprehensive classification of these neurons is still lacking. The complexity of ENS is magnified by a multiple control of the central nervous system, and bidirectional communication between various central nervous areas and the gut occurs. This lends substance to the complexity of the microbiota–gut–brain axis, which represents the network governing homeostasis through nervous, endocrine, immune, and metabolic pathways. The present manuscript is dedicated to Citation: Natale, G.; Ryskalin, L.; identifying various neuronal cytotypes belonging to ENS in baseline conditions.
    [Show full text]
  • Genetic Modulation of GABA Levels in the Anterior Cingulate Cortex by GAD1 and COMT
    Neuropsychopharmacology (2010) 35, 1708–1717 & 2010 Nature Publishing Group All rights reserved 0893-133X/10 $32.00 www.neuropsychopharmacology.org Genetic Modulation of GABA Levels in the Anterior Cingulate Cortex by GAD1 and COMT 1,2 1,2 3 1,2 Stefano Marenco* , Antonina A Savostyanova , Jan Willem van der Veen , Matthew Geramita , 1,2 1,2 1 1,2 1 Alexa Stern , Alan S Barnett , Bhaskar Kolachana , Eugenia Radulescu , Fengyu Zhang , 1 1 3 1 Joseph H Callicott , Richard E Straub , Jun Shen and Daniel R Weinberger 1 2 Clinical Brain Disorders Branch, GCAP, IRP, NIMH, Bethesda, MD, USA; Unit for Multimodal Imaging Genetics, Clinical Brain Disorders Branch, 3 GCAP, IRP, NIMH, Bethesda, MD, USA; Magnetic Resonance Spectroscopy Unit, MAP, IRP, NIMH, Bethesda, MD, USA g-Aminobutyric acid (GABA)-ergic transmission is critical for normal cortical function and is likely abnormal in a variety of neuropsychiatric disorders. We tested the in vivo effects of variations in two genes implicated in GABA function on GABA concentrations in prefrontal cortex of living subjects: glutamic acid decarboxylase 1 (GAD1), which encodes GAD67, and catechol-o-methyltransferase (COMT), which regulates synaptic dopamine in the cortex. We studied six single nucleotide polymorphisms (SNPs) in GAD1 previously associated with risk for schizophrenia or cognitive dysfunction and the val158met polymorphism in COMT in 116 healthy volunteers using proton magnetic resonance spectroscopy. Two of the GAD1 SNPs (rs1978340 (p ¼ 0.005) and rs769390 (p ¼ 0.004)) showed effects on GABA levels as did COMT val158met (p ¼ 0.04). We then tested three SNPs in GAD1 (rs1978340, rs11542313, and rs769390) for interaction with COMT val158met based on previous clinical results.
    [Show full text]
  • A Novel Homozygous Mutation in GAD1 Gene Described in A
    www.nature.com/scientificreports OPEN A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs Received: 16 May 2018 Accepted: 8 October 2018 activity and dimerization of GAD67 Published: xx xx xxxx enzyme Chiara Magri 1, Edoardo Giacopuzzi 1, Luca La Via1, Daniela Bonini1, Viola Ravasio1, Mohammed E. A. Elhussiny1, Flavia Orizio2, Fabrizio Gangemi3, Paolo Valsecchi4,5, Roberto Bresciani 2, Alessandro Barbon 1, Antonio Vita4,5 & Massimo Gennarelli1,6 Recently, by whole exome sequencing of schizophrenia (SCZ) patients, we identifed a subject that was homozygous for a novel missense substitution (c.391 A > G) in the glutamate acid decarboxylase 1 (GAD1) gene. GAD1 encodes for GAD67 enzyme, catalyzing the production of gamma-aminobutyric acid (GABA) from L-glutamic acid. Here, we studied the impact of this mutation on GAD67 activity, dimerization and subcellular localization. Biochemical assay revealed that c.391 A > G reduces GAD67 enzymatic activity by ~30%, probably due to the impaired homodimerization of homozygous mutants as highlighted by proximity ligation assays. The mutational screening of 120 genes of the “GABAergic system” in a cohort of 4,225 SCZ cases and 5,834 controls (dbGaP: phs000473.v1.p2), did not identify other cases that were homozygous for ultra-rare variants in GAD1, but highlighted an increased frequency of cases that were homozygous for rare variants in genes of the GABA system (SCZ: 0.14% vs. Controls: 0.00%; p-value = 0.0055). In conclusion, this study demonstrates the functional impact of c.391 A > G variant and its biological efect makes it a good candidate as risk variant for SCZ.
    [Show full text]
  • Glutamic Acid Decarboxylase 1 Alternative Splicing
    Trifonov et al. BMC Neuroscience 2014, 15:114 http://www.biomedcentral.com/1471-2202/15/114 RESEARCH ARTICLE Open Access Glutamic acid decarboxylase 1 alternative splicing isoforms: characterization, expression and quantification in the mouse brain Stefan Trifonov, Yuji Yamashita, Masahiko Kase, Masato Maruyama and Tetsuo Sugimoto* Abstract Background: GABA has important functions in brain plasticity related processes like memory, learning, locomotion and during the development of the nervous system. It is synthesized by the glutamic acid decarboxylase (GAD). There are two isoforms of GAD, GAD1 and GAD2, which are encoded by different genes. During embryonic development the transcription of GAD1 mRNA is regulated by alternative splicing and several alternative transcripts were distinguished in human, mouse and rat. Despite the fact that the structure of GAD1 gene has been extensively studied, knowledge of its exact structural organization, alternative promoter usage and splicing have remained incomplete. Results: In the present study we report the identification and characterization of novel GAD1 splicing isoforms (GenBank: KM102984, KM102985) by analyzing genomic and mRNA sequence data using bioinformatics, cloning and sequencing. Ten mRNA isoforms are generated from GAD1 gene locus by the combined actions of utilizing different promoters and alternative splicing of the coding exons. Using RT-PCR we found that GAD1 isoforms share similar pattern of expression in different mouse tissues and are expressed early during development. Quantitative RT-PCR was used to investigate the expression of GAD1 isoforms and GAD2 in olfactory bulb, cortex, medial and lateral striatum, hippocampus and cerebellum of adult mouse. Olfactory bulb showed the highest expression of GAD1 transcripts. Isoforms 1/2 are the most abundant forms.
    [Show full text]
  • Polyclonal Antibody to GAD1 / GAD67 - Aff - Purified
    OriGene Technologies, Inc. OriGene Technologies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-888-267-4436 Phone: +49-5221-34606-0 Fax: +1-301-340-8606 Fax: +49-5221-34606-11 [email protected] [email protected] AP31805PU-N Polyclonal Antibody to GAD1 / GAD67 - Aff - Purified Alternate names: 67 kDa glutamic acid decarboxylase, GAD-67, Glutamate decarboxylase 1, Glutamate decarboxylase 67 kDa isoform Quantity: 0.1 mg Concentration: 0.1 mg/ml (based on Bradford assay readings using BSA as a standard). Background: Human Glutamic Acid Decarboxylase (GAD-67), [EC 4.1.1.15] is a 66,987 dalton protein (594 amino acids) selectively expressed in a subpopulation of GABAergic neurons of the CNS. It catalyzes the decarboxylation of glutamic acid, forming the inhibitory neurotransmitter β-amino butyric acid (GABA). It is also know as GAD-1. Uniprot ID: Q99259 NCBI: NP_000808 GeneID: 2571 Host / Isotype: Chicken / Ig Immunogen: Synthetic peptide KLH conjugated corresponding to a region near the C-terminus of this gene product, and was 100% conserved between the Human (Q99259), Mouse (P48318) and Rat (NP_058703) gene products. After repeated injections into the hens, immune eggs were collected, and the IgY fractions were purified from the yolks. These IgY fractions were then affinity purified using a peptide column. Format: State: Liquid purified (0.45 µm filter sterilized) IgY fraction. Purification: Affinity Chromatography using a peptide column. Buffer System: 10mM PBS, pH 7.2 containing 0.02% Sodium Azide as preservative. Applications: Western Blot. Immunocytochemistry. Immunohistochemistry. Recommended Dilutions: 1/2000-1/5000 for Western blots.
    [Show full text]
  • Convergent Functional Genomics of Schizophrenia: from Comprehensive Understanding to Genetic Risk Prediction
    Molecular Psychiatry (2012) 17, 887 -- 905 & 2012 Macmillan Publishers Limited All rights reserved 1359-4184/12 www.nature.com/mp IMMEDIATE COMMUNICATION Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction M Ayalew1,2,9, H Le-Niculescu1,9, DF Levey1, N Jain1, B Changala1, SD Patel1, E Winiger1, A Breier1, A Shekhar1, R Amdur3, D Koller4, JI Nurnberger1, A Corvin5, M Geyer6, MT Tsuang6, D Salomon7, NJ Schork7, AH Fanous3, MC O’Donovan8 and AB Niculescu1,2 We have used a translational convergent functional genomics (CFG) approach to identify and prioritize genes involved in schizophrenia, by gene-level integration of genome-wide association study data with other genetic and gene expression studies in humans and animal models. Using this polyevidence scoring and pathway analyses, we identify top genes (DISC1, TCF4, MBP, MOBP, NCAM1, NRCAM, NDUFV2, RAB18, as well as ADCYAP1, BDNF, CNR1, COMT, DRD2, DTNBP1, GAD1, GRIA1, GRIN2B, HTR2A, NRG1, RELN, SNAP-25, TNIK), brain development, myelination, cell adhesion, glutamate receptor signaling, G-protein-- coupled receptor signaling and cAMP-mediated signaling as key to pathophysiology and as targets for therapeutic intervention. Overall, the data are consistent with a model of disrupted connectivity in schizophrenia, resulting from the effects of neurodevelopmental environmental stress on a background of genetic vulnerability. In addition, we show how the top candidate genes identified by CFG can be used to generate a genetic risk prediction score (GRPS) to aid schizophrenia diagnostics, with predictive ability in independent cohorts. The GRPS also differentiates classic age of onset schizophrenia from early onset and late-onset disease.
    [Show full text]
  • Identifying Genes in Monoamine Nuclei That May Determine Stress Vulnerability and Depressive Behavior in Wistar–Kyoto Rats
    Neuropsychopharmacology (2006) 31, 2449–2461 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Identifying Genes in Monoamine Nuclei that may Determine Stress Vulnerability and Depressive Behavior in Wistar–Kyoto Rats 1 2 2 ,1 Kimberly A Pearson , Alisson Stephen , Sheryl G Beck and Rita J Valentino* 1Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA; 2Department of Anesthesiology and Critical Care Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA The Wistar–Kyoto (WKY) rat is stress sensitive and exhibits depressive-like behavior. The locus coeruleus (LC)–norepinephrine and dorsal raphe (DR)–serotonin systems mediate certain aspects of the stress response and have been implicated in depression. Microarray technology was used to identify gene expression differences in the LC and DR between WKY vs Sprague–Dawley (SD) rats that might account for the WKY phenotype. RNA was isolated from microdissected LC and DR, amplified, and hybridized to microarrays (1 array/ subject, n ¼ 4/group). Significance of microarray (SAM) analysis revealed increased expression of 66 genes in the LC and 19 genes in the DR and decreased expression of 33 genes in the DR of WKY rats. Hierarchical clustering identified differences in gene expression profiles of WKY vs SD rats that generally concurred with SAM. Notably, genes that encoded for enzymes involved in norepinephrine turnover, amino-acid receptors, and certain G-protein-coupled receptors were elevated in the LC of WKY rats. The DR of WKY rats showed decreased expression of genes encoding several potassium channels and neurofilament genes. The chromosomal locations of 15 genes that were differentially expressed in WKY rats were near loci identified as contributing to depressive-like behaviors in the rat.
    [Show full text]
  • Identification of Novel Genes in Human Airway Epithelial Cells Associated with Chronic Obstructive Pulmonary Disease (COPD) Usin
    www.nature.com/scientificreports OPEN Identifcation of Novel Genes in Human Airway Epithelial Cells associated with Chronic Obstructive Received: 6 July 2018 Accepted: 7 October 2018 Pulmonary Disease (COPD) using Published: xx xx xxxx Machine-Based Learning Algorithms Shayan Mostafaei1, Anoshirvan Kazemnejad1, Sadegh Azimzadeh Jamalkandi2, Soroush Amirhashchi 3, Seamas C. Donnelly4,5, Michelle E. Armstrong4 & Mohammad Doroudian4 The aim of this project was to identify candidate novel therapeutic targets to facilitate the treatment of COPD using machine-based learning (ML) algorithms and penalized regression models. In this study, 59 healthy smokers, 53 healthy non-smokers and 21 COPD smokers (9 GOLD stage I and 12 GOLD stage II) were included (n = 133). 20,097 probes were generated from a small airway epithelium (SAE) microarray dataset obtained from these subjects previously. Subsequently, the association between gene expression levels and smoking and COPD, respectively, was assessed using: AdaBoost Classifcation Trees, Decision Tree, Gradient Boosting Machines, Naive Bayes, Neural Network, Random Forest, Support Vector Machine and adaptive LASSO, Elastic-Net, and Ridge logistic regression analyses. Using this methodology, we identifed 44 candidate genes, 27 of these genes had been previously been reported as important factors in the pathogenesis of COPD or regulation of lung function. Here, we also identifed 17 genes, which have not been previously identifed to be associated with the pathogenesis of COPD or the regulation of lung function. The most signifcantly regulated of these genes included: PRKAR2B, GAD1, LINC00930 and SLITRK6. These novel genes may provide the basis for the future development of novel therapeutics in COPD and its associated morbidities.
    [Show full text]
  • Recombinant Human GAD1/GAD67 Protein Catalog Number: ATGP2838
    Recombinant human GAD1/GAD67 protein Catalog Number: ATGP2838 PRODUCT INPORMATION Expression system E.coli Domain 1-594aa UniProt No. Q99259 NCBI Accession No. NP_000808 Alternative Names Glutamate decarboxylase 1, CPSQ1, GAD, SCP PRODUCT SPECIFICATION Molecular Weight 69.3 kDa (617aa) Concentration 0.5mg/ml (determined by Bradford assay) Formulation Liquid in. 20mM Tris-HCl buffer (pH 8.0) containing 10% glycerol Purity > 80% by SDS-PAGE Tag His-Tag Application SDS-PAGE,Denatured Storage Condition Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles. BACKGROUND Description This gene encodes one of several forms of glutamic acid decarboxylase, identified as a major autoantigen in insulin-dependent diabetes. The enzyme encoded is responsible for catalyzing the production of gamma- aminobutyric acid from L-glutamic acid. A pathogenic role for this enzyme has been identified in the human pancreas since it has been identified as an autoantigen and an autoreactive T cell target in insulin-dependent diabetes. This protein may also play a role in the stiff man syndrome. Deficiency in this enzyme has been shown to lead to pyridoxine dependency with seizures. Recombinant human GAD1 protein, fused to His-tag at N- 1 Recombinant human GAD1/GAD67 protein Catalog Number: ATGP2838 terminus, was expressed in E. coli. Amino acid Sequence MGSSHHHHHH SSGLVPRGSH MGSMASSTPS SSATSSNAGA DPNTTNLRPT TYDTWCGVAH GCTRKLGLKI CGFLQRTNSL EEKSRLVSAF KERQSSKNLL SCENSDRDAR FRRTETDFSN
    [Show full text]
  • Regulation of the Glutamate/Glutamine Cycle by Nitric Oxide in the Central Nervous System
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2015 Regulation of the Glutamate/glutamine Cycle by Nitric Oxide in the Central Nervous System Karthik Anderson Raju University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Biochemistry Commons, Biology Commons, and the Neuroscience and Neurobiology Commons Recommended Citation Raju, Karthik Anderson, "Regulation of the Glutamate/glutamine Cycle by Nitric Oxide in the Central Nervous System" (2015). Publicly Accessible Penn Dissertations. 1962. https://repository.upenn.edu/edissertations/1962 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1962 For more information, please contact [email protected]. Regulation of the Glutamate/glutamine Cycle by Nitric Oxide in the Central Nervous System Abstract Nitric oxide (˙NO) is a critical contributor to glutamatergic neurotransmission in the central nervous system (CNS). Much of its influence is due ot the ability of this molecule to regulate protein structure and function through its posttranslational modification of cysteine esidues,r a process known as S- nitrosylation. However, little is known about the extent of this modification and its associated functional effects in the brain under physiological conditions. We employed mass spectrometry (MS)-based methodologies to interrogate the S-nitrosocysteine proteome in wild-type (WT), neuronal nitric oxide synthase-deficient (nNOS-/-),
    [Show full text]
  • Clinical and Molecular Investigation of Rare
    CLINICAL AND MOLECULAR INVESTIGATION OF RARE CONGENITAL DEFECTS OF THE PALATE RIMANTE SESELGYTE A thesis submitted for the degree of Doctor of Philosophy to University College London August 2019 page Title 1 DECLARATION I, Rimante Seselgyte, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signed……………………….. Declaration 3 ABSTRACT Cleft palate (CP) affects around 1/1500 live births and, along with cleft lip, is one of the most common forms of birth defect. The studies presented here focus on unusual defects of the palate, especially to understand better the rarely reported but surprisingly common condition called submucous cleft palate (SMCP). The frequency and consequences of SMCP from a surgical perspective were first investigated based on the caseload of the North Thames Cleft Service at Great Ormond Street Hospital and St Andrew's Centre, Broomfield Hospital, Mid Essex Hospitals Trust. It was previously reported that up to 80% of individuals with unrepaired SMCP experience speech difficulties as a consequence of velopharyngeal insufficiency (VPI). Attempted repair of the palatal defect can sometimes give poor results, so controversies still exist about the correct choice of surgical technique to use. Over 23 years, 222 patients at The North Thames Cleft Service underwent operations to manage SMCP. Nearly half of them (42.8%) were diagnosed with 22q11.2 deletion syndrome (22q11.2 DS). The first operation was palate repair, with an exception of one case, followed by a second surgical intervention required in approximately half of the patients.
    [Show full text]
  • GAD1 Mrna Expression and DNA Methylation in Prefrontal Cortex of Subjects with Schizophrenia
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 2007-08-30 GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia Hsien-Sung Huang University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Medicine and Health Sciences Commons, and the Neuroscience and Neurobiology Commons Repository Citation Huang H, Akbarian S. (2007). GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. Open Access Articles. https://doi.org/10.1371/journal.pone.0000809. Retrieved from https://escholarship.umassmed.edu/oapubs/1348 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. GAD1 mRNA Expression and DNA Methylation in Prefrontal Cortex of Subjects with Schizophrenia Hsien-Sung Huang1, Schahram Akbarian2* 1 Graduate School of Biomedical Sciences, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America, 2 Department of Psychiatry, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America Dysfunction of prefrontal cortex in schizophrenia includes changes in GABAergic mRNAs, including decreased expression of GAD1, encoding the 67 kDa glutamate decarboxylase (GAD67) GABA synthesis enzyme. The underlying molecular mechanisms remain unclear. Alterations in DNA methylation as an epigenetic regulator of gene expression are thought to play a role but this hypothesis is difficult to test because no techniques are available to extract DNA from GAD1 expressing neurons efficiently from human postmortem brain.
    [Show full text]